Key result
Transcatheter mitral valve edge-to-edge repair demonstrated a 93% posterior probability of reducing all-cause mortality (HR 0.80) compared to medical therapy alone in patients with heart failure.
Why the study?
Randomized clinical trials of M-TEER for secondary mitral regurgitation in heart failure showed conflicting outcomes and frequentist meta-analyses reported no significant mortality reduction despite large treatment effect estimates.
Among patients with secondary mitral regurgitation and heart failure, does mitral valve edge-to-edge repair reduce mortality and heart failure hospitalization?
Meta-Analysis (n=1,423)
Among patients with secondary mitral regurgitation and heart failure, does mitral valve edge-to-edge repair reduce mortality and heart failure hospitalization?
Hazard Ratio: 0.8 (95% CI 0.61–1.14)
A Bayesian meta-analysis demonstrates a high posterior probability (>90%) that M-TEER provides clinically meaningful reductions in both all-cause mortality and heart failure hospitalizations, providing more nuanced evidence of benefit than traditional frequentist P-value analyses.
ranscatheter mitral valve edge-to-edge repair (M-TEER) is a minimally invasive method for reapproximating mitral leaflets in secondary mitral regurgitation (MR) resulting from displaced papillary muscles in dilated cardio-myopathies. Randomized clinical trials have shown conflicting outcomes resulting in meta-analyses to understand pooled treatment effects. However, frequentist methodological limitations led authors to conclude there was “no significant reduction in all-cause or cardiovascular (CV) mortality” in the most recent meta-analysis, despite large point estimates of treatment effects (pooled HR of 0.76 and 0.77, respectively). 1 Given that a P value marginally above 0.05 does not provide information about the true probability of treatment benefit with little clinical guidance, we conducted a Bayesian random-effects meta-analysis to reanalyze this finding. Our review was registered on PROSPERO (https:// www.crd.york.ac.uk/PROSPERO/view/CRD420261301624) and performed in accordance with PRISMA guidelines. This study was exempt from Institutional Review Board approval. A systematic search was conducted (February 21, 2026) using PubMed/MEDLINE and ClinicalTrials.gov for randomized clinical trials enrolling adults with heart failure (HF) and at least moderate MR, comparing currently approved M-TEER devices plus guideline-directed medical therapy vs guideline-directed medical therapy alone (full search strategy available in protocol). Trials of primary MR, nonapproved devices, or highly-specific populations were excluded. Study-level data were independently extracted from primary publications, using the
No takes yet. Share an insight, caveat, or question.
Schurr et al. (2026) conducted a meta-analysis in Secondary mitral regurgitation and heart failure (n=1,423). Transcatheter mitral valve edge-to-edge repair (M-TEER) vs. Guideline-directed medical therapy alone was evaluated on All-cause mortality (HR 0.80, 95% CI 0.61-1.14). Transcatheter mitral valve edge-to-edge repair demonstrated a 93% posterior probability of reducing all-cause mortality (HR 0.80) compared to medical therapy alone in patients with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: